TRINETRA › Sectors › Healthcare
Metropolis Healthcare Limited (METROPOLIS) — share price, P/E and fundamentals
Metropolis Healthcare Limited (NSE: METROPOLIS) closed at ₹545.65 on 30 Oct 2026, +12.6% over one year, against a 52-week range of ₹412.25 – ₹609.05.
In the quarter ended 30 Jun 2026 (consolidated, filed 4 Aug 2026) it reported revenue of ₹450 cr and net profit of ₹57 cr, a 12.6% net margin; revenue grew 16.6% and profit grew 26.9% year on year.
On four consecutive filed quarters its trailing P/E is 56.1; since 13 May 2025 its own P/E has ranged from 51.9 to 79.1 (median 61.0), and today's reading is higher than 10% of those 363 trading days.
From the balance sheet dated 31 Mar 2026: return on equity 15.0%, ROCE 18.6%, debt-to-equity 0.01, Piotroski F-score 7 of 9.
Against 65 Healthcare peers on NSE: Net margin higher than 48% of 63 sector peers; PBT margin higher than 48% of 63 sector peers; ROE higher than 56% of 63 sector peers.
Key figures
| Last close | ₹545.65 (30 Oct 2026) |
|---|---|
| Change 1 month / 6 months / 1 year | -6.4% / +16.8% / +12.6% |
| 52-week low – high | ₹412.25 – ₹609.05 |
| Market capitalisation | ₹11,313 cr |
| Trailing P/E | 56.1 |
| Price / book | 7.48 |
| EV / EBITDA | 25.8 |
| Earnings yield | 1.8% |
| TTM EPS | ₹9.72 |
| TTM net profit | ₹202 cr |
| Quarter revenue | ₹450 cr |
| Quarter net profit | ₹57 cr |
| Net margin | 12.6% |
| Revenue growth (YoY) | +16.6% |
| Profit growth (YoY) | +26.9% |
| Return on equity | 15.0% |
| ROCE | 18.6% |
| Debt / equity | 0.01 |
| Current ratio | 1.40 |
| Free cash flow | ₹307 cr |
| Piotroski F-score | 7 / 9 |
| Average daily turnover (50 days) | ₹10.9 cr |
Against Healthcare peers
| Metric | METROPOLIS | Peer median | Percentile |
|---|---|---|---|
| Net margin | 12.59 | 12.89 | 48 |
| PBT margin | 17.26 | 17.68 | 48 |
| ROE | 14.98 | 13.86 | 56 |
| ROCE | 18.60 | 16.59 | 62 |
| Debt / equity | 0.01 | 0.11 | 28 |
| Cash conversion | 1.83 | 1.25 | 79 |
| Trailing P/E | 56.11 | 43.07 | 66 |
| P/B | 7.48 | 5.88 | 66 |
Questions
What is the P/E ratio of Metropolis Healthcare Limited?
Metropolis Healthcare Limited's trailing P/E is 56.1, using the close of 30 Oct 2026 and earnings over the four filed quarters to 30 Jun 2026. Since 13 May 2025 its P/E has ranged 51.9–79.1.
What were Metropolis Healthcare Limited's latest quarterly results?
For the quarter ended 30 Jun 2026, Metropolis Healthcare Limited reported revenue of ₹450 cr and net profit of ₹57 cr (consolidated), filed with the exchange on 4 Aug 2026.
What is Metropolis Healthcare Limited's ROE?
Return on equity is 15.0% based on the balance sheet dated 31 Mar 2026.
Does Metropolis Healthcare Limited have debt?
Debt-to-equity is 0.01 on the balance sheet dated 31 Mar 2026.
What is METROPOLIS's 52-week high and low?
Over the last 52 weeks to 30 Oct 2026, METROPOLIS traded between ₹412.25 and ₹609.05.
Other Healthcare stocks
- Sun Pharmaceutical Industries Limited (SUNPHARMA)
- Divi's Laboratories Limited (DIVISLAB)
- Torrent Pharmaceuticals Limited (TORNTPHARM)
- Laurus Labs Limited (LAURUSLABS)
- Zydus Lifesciences Limited (ZYDUSLIFE)
- Apollo Hospitals Enterprise Limited (APOLLOHOSP)
- Dr. Reddy's Laboratories Limited (DRREDDY)
- Cipla Limited (CIPLA)
- Mankind Pharma Limited (MANKIND)
- Aurobindo Pharma Limited (AUROPHARMA)
- Lupin Limited (LUPIN)
- Max Healthcare Institute Limited (MAXHEALTH)
Source: consolidated SEBI Integrated Filing for the quarter ended 30 Jun 2026 and NSE daily closes. Open the interactive terminal view for charts and the full statements.
TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing. Figures are as filed with NSE/SEBI and as of the dates shown; they are not live prices.